Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Relay Therapeutics, Inc.NASDAQ: RLAY

Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026

Accumulated OCI remains negative

Q2 FY2026 Accumulated OCI was -$1.55M, compared with -$163K a year earlier.

Context

  • Accumulated OCI amounted to 0.2% of total assets at the end of Q2 FY2026, up 0.1 pp from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -852.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.55M-802.9% QoQ
Last fiscal yearDec 2025
$733K+174.0% YoY
Year agoJun 2025
-$163K-852.8% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-852.8%——
1 year+174.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
733K USD
Year-over-year change
+174.0%

Accumulated OCI vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's Jun 2026 Accumulated OCI of -$1.55M is the 7th highest of the 11 companies compared; the peer median is -$392K.
  • Its year-over-year change of -852.8% is the 8th highest of 11, against a peer median of -499.3%.
  • Accumulated OCI amounts to 0.2% of total assets for RLAY, versus a peer median of 0.1%.
RLAY Competitors Peer median
Accumulated OCI for RLAY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
TYRATyra Biosciences, Inc.Mar 2026$107K -84.4%—0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026-$41K -441.7%—0.0%
NRIXNurix Therapeutics, Inc.Aug 2026-$210K -276.5%—0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026-$270K -1488.2%—0.1%
ORICORIC Pharmaceuticals, Inc.Mar 2026-$290K -238.8%—0.1%
IDYAIDEAYA Biosciences, Inc.Mar 2026-$494K -131.2%—0.0%
RLAYRelay Therapeutics, Inc.Jun 2026-$1.55M -852.8%—0.2%
ERASErasca, Inc.Sep 2026-$4.19M -744.8%—0.4%
TNGXTango Therapeutics, Inc.Sep 2026-$4.51M -3825.7%—0.4%
RVMDRevolution Medicines, Inc.Jun 2026-$5.95M -557.0%—0.1%
KYMRKymera Therapeutics, Inc.Jun 2026-$7.16M -2665.2%—0.4%
Peer median (excluding RLAY) -$392K-499.3%—0.1%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents280.12M151.79M143.74M124.29M84.02M
Short-term Investments677.95M847.12M606.35M657.04M470.5M
Net Receivables4.94M5.22M000
Inventory012.11M000
Other Current Assets1.76M3.26M3.32M10.53M5.97M
Total Current Assets976.24M1.02B770.1M809.2M578.28M
Property, Plant & Equipment (Net)27.32M75.39M68.87M57.67M41.72M
Goodwill00000
Intangible Assets2.3M2.3M2.3M2.3M0
Long-term Investments02.58M2.71M01.34M
Tax Assets0(2.58M)000
Other Non-current Assets2.58M2.58M02.12M0
Total Non-current Assets32.2M80.27M73.88M62.09M43.05M
Total Assets1.01B1.1B843.98M871.3M621.33M
Account Payables8.28M10.58M9.21M14.1M7.71M
Short-term Debt00000
Tax Payables00000
Deferred Revenue248K007.68M0
Other Current Liabilities989K26.15M1.91M2.1M463K
Total Current Liabilities24.32M63.71M30.27M50.73M25.58M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65.26M32.38M13.21M00
Total Non-current Liabilities86.31M85.84M61.71M42.78M28.69M
Total Liabilities110.64M149.55M91.98M93.5M54.27M
Common Stock109K121K127K168K168K
Retained Earnings(768.1M)(1.06B)(1.4B)(1.74B)(2.01B)
Accumulated OCI(1.09M)(10.42M)(196K)(991K)733K
Other Stockholders Equity00000
Minority Interest00000
Total Equity897.81M950.22M752M777.79M567.06M
Total Debt22.9M57.74M53.47M48.5M32.46M
Net Debt(257.22M)(94.05M)(90.27M)(75.79M)(51.56M)

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.